BofA update shows where active managers are putting money
Investing.com -- Teva Pharmaceutical Industries Ltd ADR (NYSE:TEVA) stock rose 2.7% after the company announced FDA approval and U.S. launch of its generic version of Saxenda (liraglutide injection), marking the first-ever generic GLP-1 drug specifically indicated for weight loss.
The generic liraglutide injection addresses growing demand for weight loss therapies in the U.S. market. It’s approved for adults with obesity or overweight who have weight-related medical problems, as well as pediatric patients aged 12-17 years weighing more than 60 kg with obesity.
"With this approval, and by launching a generic for Saxenda (liraglutide injection), we will provide patients in the U.S. the first ever generic GLP-1 product specifically indicated for weight loss," said Ernie Richardsen, SVP, Head of U.S. Commercial Generics at Teva.
This represents Teva’s fifth first-to-market generic entry this year, supporting the company’s "Pivot to Growth Strategy" with its focus on complex generic medicines. The reference drug, Saxenda, had annual sales of $165 million as of June 2025.
Liraglutide injection is a glucagon-like peptide-1 (GLP-1) receptor agonist that must be used in combination with a reduced-calorie diet and increased physical activity. The medication is not recommended for people already taking liraglutide or other GLP-1 receptor agonists.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.